This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal
by Zacks Equity Research
Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.
LabCorp's (LH) Base Testing Volume Grows, Costs Rise
by Zacks Equity Research
LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.
Here's Why You Should Retain Haemonetics (HAE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.
3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks
by Zacks Equity Research
Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.
Cardinal Health (CAH) Buys Bendcare CPO-GPO, Invests in Its MSO
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly boost its distribution opportunities and improve patient service.
LabCorp (LH) to Offer Monkeypox Test, Double CDC's Capacity
by Zacks Equity Research
Labcorp (LH) is set to become the first national laboratory to offer this PCR test, verified for the CDC.
AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $110.47, moving -0.11% from the previous trading session.
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Reasons Why You Should Invest in ResMed (RMD) Stock Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
Study Favors Masimo's (MASI) SafetyNet for Better Patient Outcome
by Zacks Equity Research
Masimo's (MASI) SafetyNet is expected to reduce the duration of hospitalization for COVID-19 patients and create more bed capacity in hospitals.
Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Bruker (BRKR) International Growth Strong Amid Competition
by Zacks Equity Research
Bruker (BRKR) Nano Group's microelectronics and semiconductor metrology tools continue to perform well with ongoing strength in bookings and backlog.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why Investors Should Retain Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
3 Reasons to Add QuidelOrtho (QDEL) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Here's Why You Should Buy ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
LabCorp (LH) to Strengthen Laboratory Footprint in Japan
by Zacks Equity Research
LabCorp's (LH) Drug Development arm, in collaboration with BML, will open a 4,000-square meters lab facility in Kawagoe for global clinical trials.
3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
NuVasive (NUVA) to Expand in APAC With New Experience Center
by Zacks Equity Research
NuVasive's (NUVA) Singapore Experience Center will complement the flagship Experience Centers in San Diego and the New York metropolitan area.
Reasons to Add Patterson Companies (PDCO) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to its robust segmental results and the ongoing Cantel Medical integration.
Cigna (CI) Divests Units to Chubb for Net $5.1 Billion
by Zacks Equity Research
Cigna (CI) closes the deal to divest its life, accident and supplemental benefits businesses to Chubb. CI primarily intends to pursue share repurchases with proceeds received from the transaction.
Quest Diagnostics' (DGX) Base Business Grows Despite Margin Woes
by Zacks Equity Research
Quest Diagnostics (DGX) continues to make inroads with its health plans, gaining share and increasing revenues faster than the market.